(SYK) Stryker - Ratings and Ratios
Implants, Navigation, Endoscopy, Spine, Orthobiologics
SYK EPS (Earnings per Share)
SYK Revenue
Description: SYK Stryker September 25, 2025
Stryker Corporation (NYSE: SYK) is a diversified medical-technology firm that operates two primary business segments: MedSurg & Neurotechnology and Orthopaedics. The MedSurg & Neurotechnology segment supplies a broad portfolio that includes surgical equipment, navigation and endoscopic systems, AI-enabled virtual-care platforms, acute-stroke minimally invasive devices, cranial and maxillofacial products, as well as orthobiologic materials such as synthetic bone grafts and vertebral-augmentation solutions. The Orthopaedics segment focuses on implants for total joint replacements (hip, knee, shoulder), trauma and extremities, plus thoracolumbar fixation and minimally invasive spinal systems.
The company distributes its products directly and through third-party dealers in roughly 75 countries, serving physicians, hospitals, and other healthcare facilities. Founded in 1941, Stryker is headquartered in Portage, Michigan, and has grown through both organic innovation and strategic acquisitions (e.g., the 2022 purchase of Wright Medical for $4.7 bn, expanding its trauma and extremities footprint).
Key performance indicators from the most recent FY 2023 filing show revenue of $21.0 bn (+6 % YoY), operating margin of 15.8 % (up from 14.9 % in FY 2022), and a 12-month trailing R&D spend of $1.9 bn (≈9 % of sales). The orthopaedic implant market is driven by an aging U.S. population and rising joint-replacement volumes, with the American Joint Replacement Registry estimating >1 million procedures annually-a secular tailwind that underpins Stryker’s growth outlook. However, the segment remains sensitive to reimbursement policy shifts and potential supply-chain disruptions in high-mix, low-volume surgical devices.
For a deeper quantitative assessment of Stryker’s valuation dynamics-including forward cash-flow models and peer-adjusted multiples-exploring the analytics on ValueRay can provide the granular data needed to refine your investment thesis.
SYK Stock Overview
| Market Cap in USD | 148,469m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1988-02-01 |
SYK Stock Ratings
| Growth Rating | 65.9% |
| Fundamental | 66.0% |
| Dividend Rating | 58.0% |
| Return 12m vs S&P 500 | -11.0% |
| Analyst Rating | 4.06 of 5 |
SYK Dividends
| Dividend Yield 12m | 0.89% |
| Yield on Cost 5y | 1.75% |
| Annual Growth 5y | 8.30% |
| Payout Consistency | 96.5% |
| Payout Ratio | 28.7% |
SYK Growth Ratios
| Growth Correlation 3m | -41.6% |
| Growth Correlation 12m | 20.5% |
| Growth Correlation 5y | 86.9% |
| CAGR 5y | 20.94% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.26 |
| CAGR/Mean DD 3y (Pain Ratio) | 4.66 |
| Sharpe Ratio 12m | -0.54 |
| Alpha | -13.88 |
| Beta | 0.951 |
| Volatility | 19.61% |
| Current Volume | 1030.7k |
| Average Volume 20d | 1352.7k |
| Stop Loss | 364.6 (-3%) |
| Signal | -0.28 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (2.92b TTM) > 0 and > 6% of Revenue (6% = 1.43b TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 23.99% (prev 22.06%; Δ 1.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 4.77b > Net Income 2.92b (YES >=105%, WARN >=100%) |
| Net Debt (14.75b) to EBITDA (4.61b) ratio: 3.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (386.4m) change vs 12m ago 0.26% (target <= -2.0% for YES) |
| Gross Margin 62.19% (prev 61.21%; Δ 0.98pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.74% (prev 54.66%; Δ 1.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 22.08 (EBITDA TTM 4.61b / Interest Expense TTM 159.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.51
| (A) 0.12 = (Total Current Assets 13.00b - Total Current Liabilities 7.29b) / Total Assets 46.33b |
| (B) 0.42 = Retained Earnings (Balance) 19.42b / Total Assets 46.33b |
| (C) 0.08 = EBIT TTM 3.51b / Avg Total Assets 42.73b |
| (D) 0.74 = Book Value of Equity 18.70b / Total Liabilities 25.14b |
| Total Rating: 3.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.02
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 2.47% = 1.23 |
| 3. FCF Margin 16.89% = 4.22 |
| 4. Debt/Equity 0.81 = 2.18 |
| 5. Debt/Ebitda 3.20 = -2.02 |
| 6. ROIC - WACC (= -0.21)% = -0.27 |
| 7. RoE 14.08% = 1.17 |
| 8. Rev. Trend 84.88% = 6.37 |
| 9. EPS Trend 22.60% = 1.13 |
What is the price of SYK shares?
Over the past week, the price has changed by -1.01%, over one month by +1.87%, over three months by -5.97% and over the past year by +6.55%.
Is Stryker a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SYK is around 372.39 USD . This means that SYK is currently overvalued and has a potential downside of -0.94%.
Is SYK a buy, sell or hold?
- Strong Buy: 13
- Buy: 9
- Hold: 9
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SYK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 429.4 | 14.2% |
| Analysts Target Price | 429.4 | 14.2% |
| ValueRay Target Price | 415.7 | 10.6% |
SYK Fundamental Data Overview October 25, 2025
P/E Trailing = 50.7364
P/E Forward = 24.3902
P/S = 6.2335
P/B = 6.6102
P/EG = 1.864
Beta = 0.951
Revenue TTM = 23.82b USD
EBIT TTM = 3.51b USD
EBITDA TTM = 4.61b USD
Long Term Debt = 14.83b USD (from longTermDebt, last quarter)
Short Term Debt = 1.91b USD (from shortTermDebt, last quarter)
Debt = 17.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.75b USD (from netDebt column, last quarter)
Enterprise Value = 163.22b USD (148.47b + Debt 17.13b - CCE 2.38b)
Interest Coverage Ratio = 22.08 (Ebit TTM 3.51b / Interest Expense TTM 159.0m)
FCF Yield = 2.47% (FCF TTM 4.02b / Enterprise Value 163.22b)
FCF Margin = 16.89% (FCF TTM 4.02b / Revenue TTM 23.82b)
Net Margin = 12.25% (Net Income TTM 2.92b / Revenue TTM 23.82b)
Gross Margin = 62.19% ((Revenue TTM 23.82b - Cost of Revenue TTM 9.01b) / Revenue TTM)
Gross Margin QoQ = 62.27% (prev 62.73%)
Tobins Q-Ratio = 3.52 (Enterprise Value 163.22b / Total Assets 46.33b)
Interest Expense / Debt = 0.93% (Interest Expense 159.0m / Debt 17.13b)
Taxrate = 12.99% (132.0m / 1.02b)
NOPAT = 3.05b (EBIT 3.51b * (1 - 12.99%))
Current Ratio = 1.78 (Total Current Assets 13.00b / Total Current Liabilities 7.29b)
Debt / Equity = 0.81 (Debt 17.13b / totalStockholderEquity, last quarter 21.19b)
Debt / EBITDA = 3.20 (Net Debt 14.75b / EBITDA 4.61b)
Debt / FCF = 3.67 (Net Debt 14.75b / FCF TTM 4.02b)
Total Stockholder Equity = 20.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.30% (Net Income 2.92b / Total Assets 46.33b)
RoE = 14.08% (Net Income TTM 2.92b / Total Stockholder Equity 20.73b)
RoCE = 9.87% (EBIT 3.51b / Capital Employed (Equity 20.73b + L.T.Debt 14.83b))
RoIC = 8.40% (NOPAT 3.05b / Invested Capital 36.34b)
WACC = 8.62% (E(148.47b)/V(165.60b) * Re(9.52%) + D(17.13b)/V(165.60b) * Rd(0.93%) * (1-Tc(0.13)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.33%
[DCF Debug] Terminal Value 76.28% ; FCFE base≈3.54b ; Y1≈4.23b ; Y5≈6.71b
Fair Price DCF = 230.7 (DCF Value 88.18b / Shares Outstanding 382.3m; 5y FCF grow 20.87% → 3.0% )
EPS Correlation: 22.60 | EPS CAGR: 15.22% | SUE: 0.24 | # QB: 0
Revenue Correlation: 84.88 | Revenue CAGR: 11.37% | SUE: 1.35 | # QB: 4
Additional Sources for SYK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle